Neoadjuvant therapy for gastroesophageal adenocarcinoma
نویسندگان
چکیده
منابع مشابه
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
OBJECTIVE This study was conducted to investigate the efficacy and safety of using a concurrent neoadjuvant chemoradiotherapy (a XELOX regimen) to treat adenocarcinoma of the gastroesophageal junction. METHODS Seventy-six patients having resectable adenocarcinoma at the gastroesophageal junction (T3/4, N+, M0) were recruited to participate and randomly assigned to either a chemoradiotherapy g...
متن کاملIN TRAOPERATIVE RADIATION THERAPY FOR GASTRIC ADENOCARCINOMA
Intraoperative radiation therapy (IORT) is a multidisciplinary approach in which residual tumors or tumor beds are directly irradiated during a surgical procedure. To evaluate its efficacy, from 1985, we conducted a prospective study including non-metastatic gastric adenocarcinoma treated by surgery, IORT (15 Grays) and postoperative external beam radiotherapy (44 Grays). Up to 1993, 51 ca...
متن کاملHER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
Despite ongoing advances in the treatment of gastroesophageal cancer, prognosis remains poor. The best promise to improve this poor survival is provided by new targeted agents. Of these, human epidermal growth factor receptor 2 (HER2) is currently in the spotlight. In this review, we provide an overview of recent developments in HER2 testing and results of clinical trials targeting HER2 in gast...
متن کاملNeoadjuvant chemoradiation for adenocarcinoma of the pancreas.
Pancreaticoduodenectomy is performed on carefully selected patients as part of a protocol-based clinical research program emphasizing the importance of multimodality management for patients with potentially resectable adenocarcinoma of the pancreatic head. Treatment schemas emphasize the importance of minimizing toxicity and treatment duration, while attempting to improve therapeutic efficacy. ...
متن کاملNeoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes
There has been an alarming rise in the incidence of esophageal adenocarcinoma which continues to have poor survival rates primarily due to lack of effective chemotherapy and presentation at advanced stages. Over a dozen chemotherapeutic agents are FDA approved for esophageal cancer (EC), and a two or three-drug combination is typically prescribed as first-line therapy for the majority of EC pat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: World Journal of Clinical Oncology
سال: 2016
ISSN: 2218-4333
DOI: 10.5306/wjco.v7.i3.284